

PRINCIPAL INVESTIGATOR AGREEMENT

STUDY TITLE :

IRIS PHARMA Study Number:

Study Director and Testing Facility

Address

IRIS PHARMA
Z.I. Les Nertières
Allée Hector Pintus
FR-06610 LA GAUDE

Study Director

IRIS PHARMA
Tel: +33 493 59-4959
Fax: +33 493 59-4950
e-mail:

Principal Investigator and Test Site (to be completed)

Address

Principal Investigator

Name :
Tel:
Fax:
e-mail:

Delegated phase:

Test site study reference number:

This Principal Investigator Agreement should be completed and signed by the Principal Investigator and Test Site management representative. The original signed version should be returned to the Study Director prior to the start of the phase.

The Study Director and Principal Investigator will inform each other in a timely manner of all relevant information, deviation amendment concerning this phase.

The Study Director and Principal Investigator will preferably communicate via e-mail in order to assure traceability of the exchanges. All relevant exchanges will be kept in the study archives.

PRINCIPAL INVESTIGATOR AGREEMENT

Principal Investigator

The Principal Investigator below agrees to perform the study phase under his responsibility according to this definitive study plan number XXX and in accordance with GLP regulations (OECD "Principles of Good Laboratory Practice Regulations" ENV/MC/CHM(98), OECD "Principles of GLP to the organization and management of multisites studies ENV/JM/MONO(2002)9).

Name:

Signature:

Date:

Management Representative

The manager below certifies that the Principal Investigator cited in this agreement has the adequate qualifications, training and experience to perform the delegated phase.

Printed Name:

Signature:

Date:
